Rukiye Tekdemir, Fatih Ekici, Hasan Ali Güler, Muhammet Tuğrul Ergün, Yavuz Selvi
{"title":"<s:1> rkiye双相情感障碍患者代谢综合征的风险:一年随访研究。","authors":"Rukiye Tekdemir, Fatih Ekici, Hasan Ali Güler, Muhammet Tuğrul Ergün, Yavuz Selvi","doi":"10.1177/00912174251350817","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveThis study examined the incidence of metabolic syndrome (MetS) in 100 individuals with bipolar disorder (BD) and identified clinical and biological predictors of incident MetS during a 1-year follow-up.MethodsThe study included euthymic BD type-1 patients consecutively recruited from outpatient clinics between July 2023 and July 2024. MetS was defined according to International Diabetes Federation criteria. Patients without MetS at baseline but with MetS during follow-up were classified as having incident MetS. A logistic regression model was utilized to estimate the adjusted odds ratios (OR) and corresponding 95% confidence intervals (CIs) for associations between predictors and incident MetS.ResultsOf the 100 participants enrolled in the study (92% response rate), 29% met MetS criteria at baseline. Of the 71 without baseline MetS, 29 (40.8%) developed MetS over a 1-year period. Significant predictors of MetS onset included a higher number of manic/hypomanic episodes (OR = 1.459, 95% CI = 1.005-2.118, <i>P</i> = .047), increased chlorpromazine-equivalent antipsychotic dosages (OR = 1.007, 95% CI = 1.001-1.013, <i>P</i> = .024), high waist circumference (OR = 1.247, 95% CI = 1.052-1.479, <i>P</i> = .011), and hypertriglyceridemia (OR = 1.041, 95% CI = 1.007-1.077, <i>P</i> = .020). Conversely, lamotrigine use was inversely associated with MetS development (OR = 0.030, 95% CI = 0.001-0.659, <i>P</i> = .026).ConclusionA high incidence of MetS (41%) was observed within 1 year among patients with BD. Identified risk factors highlight opportunities for intervention through mood recurrence prevention, careful pharmacotherapy management, and treatment of pre-existing components of MetS.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":" ","pages":"912174251350817"},"PeriodicalIF":1.3000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of metabolic syndrome in patients with bipolar disorder in Türkiye: A one-year follow-up study.\",\"authors\":\"Rukiye Tekdemir, Fatih Ekici, Hasan Ali Güler, Muhammet Tuğrul Ergün, Yavuz Selvi\",\"doi\":\"10.1177/00912174251350817\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectiveThis study examined the incidence of metabolic syndrome (MetS) in 100 individuals with bipolar disorder (BD) and identified clinical and biological predictors of incident MetS during a 1-year follow-up.MethodsThe study included euthymic BD type-1 patients consecutively recruited from outpatient clinics between July 2023 and July 2024. MetS was defined according to International Diabetes Federation criteria. Patients without MetS at baseline but with MetS during follow-up were classified as having incident MetS. A logistic regression model was utilized to estimate the adjusted odds ratios (OR) and corresponding 95% confidence intervals (CIs) for associations between predictors and incident MetS.ResultsOf the 100 participants enrolled in the study (92% response rate), 29% met MetS criteria at baseline. Of the 71 without baseline MetS, 29 (40.8%) developed MetS over a 1-year period. Significant predictors of MetS onset included a higher number of manic/hypomanic episodes (OR = 1.459, 95% CI = 1.005-2.118, <i>P</i> = .047), increased chlorpromazine-equivalent antipsychotic dosages (OR = 1.007, 95% CI = 1.001-1.013, <i>P</i> = .024), high waist circumference (OR = 1.247, 95% CI = 1.052-1.479, <i>P</i> = .011), and hypertriglyceridemia (OR = 1.041, 95% CI = 1.007-1.077, <i>P</i> = .020). Conversely, lamotrigine use was inversely associated with MetS development (OR = 0.030, 95% CI = 0.001-0.659, <i>P</i> = .026).ConclusionA high incidence of MetS (41%) was observed within 1 year among patients with BD. Identified risk factors highlight opportunities for intervention through mood recurrence prevention, careful pharmacotherapy management, and treatment of pre-existing components of MetS.</p>\",\"PeriodicalId\":50294,\"journal\":{\"name\":\"International Journal of Psychiatry in Medicine\",\"volume\":\" \",\"pages\":\"912174251350817\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Psychiatry in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00912174251350817\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00912174251350817","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
摘要
目的研究100例双相情感障碍(BD)患者代谢综合征(MetS)的发生率,并在1年的随访中确定代谢综合征发生的临床和生物学预测因素。方法研究对象为2023年7月至2024年7月在门诊连续招募的健康BD 1型患者。MetS是根据国际糖尿病联合会的标准定义的。基线时无MetS但随访时有MetS的患者被归类为偶发性MetS。使用逻辑回归模型来估计预测因子与事件MetS之间的校正比值比(OR)和相应的95%置信区间(CIs)。结果在100名参与者中(92%的应答率),29%的人在基线时符合MetS标准。在71例没有基线MetS的患者中,29例(40.8%)在1年内发展为MetS。MetS发病的重要预测因子包括较高的躁狂/轻躁发作次数(OR = 1.459, 95% CI = 1.005-2.118, P = 0.047)、氯丙嗪等效抗精神病药物剂量增加(OR = 1.007, 95% CI = 1.001-1.013, P = 0.024)、高腰围(OR = 1.247, 95% CI = 1.052-1.479, P = 0.011)和高甘油三酯血症(OR = 1.041, 95% CI = 1.007-1.077, P = 0.020)。相反,拉莫三嗪的使用与MetS的发生呈负相关(OR = 0.030, 95% CI = 0.001-0.659, P = 0.026)。结论:在BD患者中,1年内MetS的发生率很高(41%)。已确定的危险因素突出了通过情绪复发预防、仔细的药物治疗管理和治疗MetS已有成分进行干预的机会。
Risk of metabolic syndrome in patients with bipolar disorder in Türkiye: A one-year follow-up study.
ObjectiveThis study examined the incidence of metabolic syndrome (MetS) in 100 individuals with bipolar disorder (BD) and identified clinical and biological predictors of incident MetS during a 1-year follow-up.MethodsThe study included euthymic BD type-1 patients consecutively recruited from outpatient clinics between July 2023 and July 2024. MetS was defined according to International Diabetes Federation criteria. Patients without MetS at baseline but with MetS during follow-up were classified as having incident MetS. A logistic regression model was utilized to estimate the adjusted odds ratios (OR) and corresponding 95% confidence intervals (CIs) for associations between predictors and incident MetS.ResultsOf the 100 participants enrolled in the study (92% response rate), 29% met MetS criteria at baseline. Of the 71 without baseline MetS, 29 (40.8%) developed MetS over a 1-year period. Significant predictors of MetS onset included a higher number of manic/hypomanic episodes (OR = 1.459, 95% CI = 1.005-2.118, P = .047), increased chlorpromazine-equivalent antipsychotic dosages (OR = 1.007, 95% CI = 1.001-1.013, P = .024), high waist circumference (OR = 1.247, 95% CI = 1.052-1.479, P = .011), and hypertriglyceridemia (OR = 1.041, 95% CI = 1.007-1.077, P = .020). Conversely, lamotrigine use was inversely associated with MetS development (OR = 0.030, 95% CI = 0.001-0.659, P = .026).ConclusionA high incidence of MetS (41%) was observed within 1 year among patients with BD. Identified risk factors highlight opportunities for intervention through mood recurrence prevention, careful pharmacotherapy management, and treatment of pre-existing components of MetS.
期刊介绍:
The International Journal of Psychiatry in Medicine (IJPM) bridges the gap between clinical psychiatry research and primary care clinical research. Providing a forum for addressing: The relevance of psychobiological, psychological, social, familial, religious, and cultural factors in the development and treatment of illness; the relationship of biomarkers to psychiatric symptoms and syndromes in primary care...